Literature DB >> 23006754

Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Damien Maura1, Matthieu Galtier, Chantal Le Bouguénec, Laurent Debarbieux.   

Abstract

In vivo bacteriophage targeting of enteroaggregative Escherichia coli (EAEC) was assessed using a mouse intestinal model of colonization with the O104:H4 55989Str strain and a cocktail of three virulent bacteriophages. The colonization model was shown to mimic asymptomatic intestinal carriage found in humans. The addition of the cocktail to drinking water for 24 h strongly decreased ileal and weakly decreased fecal 55989Str concentrations in a dose-dependent manner. These decreases in ileal and fecal bacterial concentrations were only transient, since 55989Str concentrations returned to their original levels 3 days later. These transient decreases were independent of the mouse microbiota, as similar results were obtained with axenic mice. We studied the infectivity of each bacteriophage in the ileal and fecal environments and found that 55989Str bacteria in the mouse ileum were permissive to all three bacteriophages, whereas those in the feces were permissive to only one bacteriophage. Our results provide the first demonstration that bacterial permissivity to infection with virulent bacteriophages is not uniform throughout the gut; this highlights the need for a detailed characterization of the interactions between bacteria and bacteriophages in vivo for the further development of phage therapy targeting intestinal pathogens found in the gut of asymptomatic human carriers.

Entities:  

Mesh:

Year:  2012        PMID: 23006754      PMCID: PMC3497199          DOI: 10.1128/AAC.00602-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Facilitation of CRISPR adaptation.

Authors:  Stephen T Abedon
Journal:  Bacteriophage       Date:  2011-05-01

2.  The bacteria fight back.

Authors:  Gary Taubes
Journal:  Science       Date:  2008-07-18       Impact factor: 47.728

3.  Phages in nature.

Authors:  Martha Rj Clokie; Andrew D Millard; Andrey V Letarov; Shaun Heaphy
Journal:  Bacteriophage       Date:  2011-01

4.  Household transmission of haemolytic uraemic syndrome associated with Escherichia coli O104:H4, south-western France, June 2011.

Authors:  B Aldabe; Y Delmas; G Gault; B Vendrely; B Llanas; M Charron; C Castor; N Ong; Fx Weill; P Mariani-Kurkdjian; F Terrier; M Desjardin; J Simoes; B Le Bihan; C Combe; P Rolland
Journal:  Euro Surveill       Date:  2011-08-04

Review 5.  Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology.

Authors:  Maite Muniesa; Jens A Hammerl; Stefan Hertwig; Bernd Appel; Harald Brüssow
Journal:  Appl Environ Microbiol       Date:  2012-04-13       Impact factor: 4.792

6.  Enteroaggregative Escherichia coli infection in a rabbit model.

Authors:  G Kang; A B Pulimood; M M Mathan; V I Mathan
Journal:  Pathology       Date:  2001-08       Impact factor: 5.306

7.  In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli.

Authors:  Marietta Weiss; Emmanuel Denou; Anne Bruttin; Ruth Serra-Moreno; Marie-Lise Dillmann; Harald Brüssow
Journal:  Virology       Date:  2009-08-21       Impact factor: 3.616

8.  Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection.

Authors:  Amy Croswell; Elad Amir; Paul Teggatz; Melissa Barman; Nita H Salzman
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

9.  Bacteriophage isolated from feedlot cattle can reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts.

Authors:  Todd R Callaway; Tom S Edrington; Andrew D Brabban; Robin C Anderson; Michelle L Rossman; Mike J Engler; Mandy A Carr; Ken J Genovese; James E Keen; Mike L Looper; Elizabeth M Kutter; David J Nisbet
Journal:  Foodborne Pathog Dis       Date:  2008-04       Impact factor: 3.171

10.  Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths.

Authors:  Marie Touchon; Claire Hoede; Olivier Tenaillon; Valérie Barbe; Simon Baeriswyl; Philippe Bidet; Edouard Bingen; Stéphane Bonacorsi; Christiane Bouchier; Odile Bouvet; Alexandra Calteau; Hélène Chiapello; Olivier Clermont; Stéphane Cruveiller; Antoine Danchin; Médéric Diard; Carole Dossat; Meriem El Karoui; Eric Frapy; Louis Garry; Jean Marc Ghigo; Anne Marie Gilles; James Johnson; Chantal Le Bouguénec; Mathilde Lescat; Sophie Mangenot; Vanessa Martinez-Jéhanne; Ivan Matic; Xavier Nassif; Sophie Oztas; Marie Agnès Petit; Christophe Pichon; Zoé Rouy; Claude Saint Ruf; Dominique Schneider; Jérôme Tourret; Benoit Vacherie; David Vallenet; Claudine Médigue; Eduardo P C Rocha; Erick Denamur
Journal:  PLoS Genet       Date:  2009-01-23       Impact factor: 5.917

View more
  37 in total

1.  Virulence of the Shiga toxin type 2-expressing Escherichia coli O104:H4 German outbreak isolate in two animal models.

Authors:  Tonia Zangari; Angela R Melton-Celsa; Aruna Panda; Nadia Boisen; Mark A Smith; Ivan Tatarov; Louis J De Tolla; James P Nataro; Alison D O'Brien
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 2.  Ménage à trois in the human gut: interactions between host, bacteria and phages.

Authors:  Mohammadali Khan Mirzaei; Corinne F Maurice
Journal:  Nat Rev Microbiol       Date:  2017-05-02       Impact factor: 60.633

Review 3.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

4.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 5.  Biological challenges of phage therapy and proposed solutions: a literature review.

Authors:  Katherine M Caflisch; Gina A Suh; Robin Patel
Journal:  Expert Rev Anti Infect Ther       Date:  2019-12-02       Impact factor: 5.091

6.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 7.  Emerging Technologies for Gut Microbiome Research.

Authors:  Jason W Arnold; Jeffrey Roach; M Andrea Azcarate-Peril
Journal:  Trends Microbiol       Date:  2016-07-15       Impact factor: 17.079

Review 8.  Phages and their potential to modulate the microbiome and immunity.

Authors:  Sara Federici; Samuel P Nobs; Eran Elinav
Journal:  Cell Mol Immunol       Date:  2020-09-08       Impact factor: 11.530

9.  The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition.

Authors:  Jeffrey K Cornuault; Elisabeth Moncaut; Valentin Loux; Aurélie Mathieu; Harry Sokol; Marie-Agnès Petit; Marianne De Paepe
Journal:  ISME J       Date:  2019-12-11       Impact factor: 10.302

Review 10.  Close Encounters of Three Kinds: Bacteriophages, Commensal Bacteria, and Host Immunity.

Authors:  Eric C Keen; Gautam Dantas
Journal:  Trends Microbiol       Date:  2018-06-13       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.